Quantitative analysis of CDX2 protein expression improves its clinical utility as a prognostic biomarker in stage II and III colon cancer
Sjoerd H. den Uil(Spaarne Gasthuis), Remond J.A. Fijneman(Dutch Cancer Society), Robbert J.C. Slebos(University of Iowa), Hein B.A.C. Stockmann(Spaarne Gasthuis), Sander R. Piersma(Amsterdam UMC Location Vrije Universiteit Amsterdam), Joyce Sanders(The Netherlands Cancer Institute), Pien M. Delis‐van Diemen(The Netherlands Cancer Institute), Veerle M.H. Coupé(Amsterdam University Medical Centers), Herman Bril(Spaarne Gasthuis), Gerrit A. Meijer(The Netherlands Cancer Institute), Thang V. Pham(Oncode Institute), Connie R. Jiménez(Amsterdam UMC Location Vrije Universiteit Amsterdam), Meike de Wit(The Netherlands Cancer Institute)
Cited by 36
Related Papers
AACR Project GENIE: Powering Precision Medicine through an International Consortium
|Cancer Discovery|2017|2k
Proteogenomic characterization of human colon and rectal cancer
|Nature|2014|1.6k
Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose
|New England Journal of Medicine|2008|1.5k
Genome-wide cell-free DNA fragmentation in patients with cancer
|Nature|2019|1.5k
Direct detection of early-stage cancers using circulating tumor DNA
|Science Translational Medicine|2017|1.1k